By supporting liver function, it keeps your metabolism balanced and efficient
In the AMPLITUDE-O trial, 15% of patients included were also receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors, yet efpeglenatide decreased the rate of MACE irrespective of whether patients were also receiving this treatment
Until Wegovys MASH indication, patients with F2F3 fibrosis lacked any FDAapproved pharmacologic therapy targeting steatohepatitis resolution and fibrosis improvement, relying primarily on lifestyle modification and bariatric surgery. Against this background, semaglutides ability to deliver sustained doubledigit percentage weight loss, improve cardiometabolic markers, reduce MACE, and favorably modify histologic endpoints in MASH positions Wegovy as a versatile agent across cardiometabolic care pathways, provided its risks and limitations are fully understood and respected
Both are valid answers, but they shape the dose, the duration, and what success looks like
Reducing agents similar to NAC, NAC-amide and NAC-methyl ester, were evaluated for their effects on oligomerization/dimerization of secreted hCC in vitro